本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SEOUL, South Korea, Jan. 22, 2024 /PRNewswire/ -- January 22, Hitachi-LG Data Storage Inc., SK hynix's global distributor and manufacturing partner, is set to launch the new "Haechi H01" heat sink designed specifically for the PlayStation 5. This innovative heat sink aims to maximize the cooling performance of the high-performance P41 internal SSD, developed by SK hynix. H01 HEATSINK To promote the product, Hitachi-LG Data Storage is planning a global Amazon promotion starting on January 22 and ending on February 4 in 9 countries: the US, Canada, Mexico, UK, Germany, France, Italy, Spain, and Australia. The Haechi H01 heat sink is crafted using advanced CNC machining technology and is designed as a single piece. It boasts a heat dissipation area approximately 2.3 times larger than that of a standard M.2 SSD heat sink. The bottom of the heat sink features Thermal Interface Material (TIM), resistant to deformation caused by heat and stress, thereby enhancing the product's durability. Hitachi-LG Data Storage Inc. has emphasized that the H01 Heatsink is tailored for high-performance gaming and can maintain stable performance by balancing fast speed and heat generation. Additionally, Hitachi LG Data Storage plans to introduce a PlayStation 5 Slim-specific M.2 SSD heat sink from SK hynix in the near future. About Hitachi-LG Data Storage Inc. Hitachi-LG Data Storage, a collaborative business entity between Hitachi and LG Electronics, is dedicated to developing top-notch storage devices and automotive in-cabin components. As the authorized manufacturing partner and global distributor of SK hynix SSDs, Hitachi-LG Data Storage ensures the highest quality standards and reliable delivery to customers worldwide.
NEW YORK, Jan. 21, 2024 /PRNewswire/ -- Dell Technologies has announced the expansion of its latest global loyalty program to Japan on Jan 18, 2024, following successful launches in Canada and the United States in 2023. In a significant move for the Web3 space, OORT, a burgeoning force in AI-focused decentralized cloud services, has joined this program, offering its OORT Storage (formerly OORT DSS) to Dell's customers. OORT: Aligning with Mass Adoption Goals for Decentralized Solutions The inclusion of OORT in Dell's loyalty program is a strategic step that resonates deeply with OORT's mission of driving the mass adoption of decentralized cloud solutions. As the program expands globally, OORT is continuously refining its offerings, making them increasingly suitable for complex and demanding applications, such as those in the field of artificial intelligence. OORT's commitment to providing enterprise-grade decentralized cloud solutions is evident in its approach to developing technology tailored for AI applications. This initiative demonstrates OORT's dedication to innovation and its role in advancing the integration of decentralized technology in mainstream business solutions. About OORT's Technology for AI Applications OORT has been diligently working on enhancing its decentralized storage services and preparing for the upcoming compute services, ensuring that they cater effectively to the burgeoning demands of AI applications. This focus is evident in their latest service updates, which have been designed to offer increased efficiency, security, and scalability – essential features for AI-driven tasks. Dell Rewards: Embracing the Future with OORT The extension of Dell Rewards to Japan marks a crucial step in Dell's journey towards integrating cutting-edge technology with customer-focused services. OORT's participation as the sole Web3 project in this program signifies a mutual commitment to innovation and customer satisfaction. Dell Rewards continues to offer an array of exclusive benefits, now enriched with OORT's decentralized storage solutions, reflecting Dell's foresight in embracing emerging technologies to benefit its vast customer base. Future Prospects As Dell Rewards forges ahead, incorporating OORT's advanced solutions in Japan and beyond, both companies are set to redefine the standards of customer engagement and technological excellence in the digital age. This partnership not only enhances the loyalty program's forward-thinking vision but also positions OORT as a trust-worthy provider of decentralized solutions, poised to impact cloud service for AI applications significantly. For more information about the Dell Rewards loyalty program and OORT's involvement, please visit https://console.oortech.com/loyalty-program/. About OORT OORT is a decentralized cloud for privacy and cost savings. By integrating global compute and storage resources, we provide AI solutions to enhance business operations. To learn more about OORT, please visit www.oortech.com or follow its Twitter at https://twitter.com/oortech.
Asian destinations and attractions among most booked; growing demand for event and sustainable travel CEO shares Asia's untapped opportunities and investment potential, highlights positive visa policies and visitor numbers Asia's growth prospects robust, potential for sustained growth in the region DAVOS, Switzerland, Jan. 20, 2024 /PRNewswire/ -- Leading global travel service provider Trip.com Group is embracing new trends and opportunities in the post-pandemic travel landscape, with its CEO Jane Sun sharing insights at the prominent World Economic Forum (WEF) Annual Meeting held in Davos, Switzerland, this week. Ms Sun also expressed optimism about Asia's continued growth and shared her perspective on its investment potential at the panel discussion titled "Asia – the world's next growth anchor?" From left to right. Moderator Mr Ben Hung, CEO, Asia, at Standard Chartered Bank; Mr Roy Gori, President and CEO of Manulife; Ms Jane Sun, CEO of Trip.com Group and Mr Geoff Lee, Executive Director, Head of Private Markets and Head of Technology at Khazanah Nasional. As major leaders from government, business, and civil society gathered to discuss the fundamental principles of driving trust in a world of fractures and uncertainties, the panel convened influential stakeholders to delve into the exciting opportunities and new challenges emerging in Asia. Speaking alongside Ms Sun were Mr Roy Gori, President and CEO of Canada's largest insurance company Manulife, and Mr Geoff Lee, Executive Director, Head of Private Markets and Head of Technology at Malaysia's sovereign wealth fund Khazanah Nasional. Mr Ben Hung, CEO, Asia, at Standard Chartered Bank, moderated the panel. With global tourism approaching a full recovery, Trip.com Group has witnessed strong booking interest in Asia, with Thailand, Japan, and South Korea among the top travel destinations. The rise in consumer income has also led to growing trends in the region such as high-quality wellness experiences and event tourism, particularly for sought-after events like concerts and music festivals. Sustainable tourism is another shift that is picking up steam, with environmental awareness motivating more than 16 million Trip.com Group customers to choose low-carbon travel options, such as hotels that adhere to sustainable standards. The Group has also prioritised options such as the rental of electronic vehicles and offering flights with lower carbon emissions. Zooming in on the post-pandemic economic trajectory in one of Asia's largest regions, Ms Sun asserted that China offers more investment opportunities than what some may have perceived. "Investors should not overlook the thriving travel, wellness or entertainment sector in China. With its vast size, diverse industries, and varying levels of consumer buying power, the investment opportunities are abundant," said Ms Sun. In particular, the travel sector presents numerous untapped growth opportunities, such as the rapid increase in inbound and outbound travel, as well as favourable policy developments. Ms Sun expressed optimism about the growth of the tourism industry, especially with recent positive developments, such as increased flight capacities and expanded visa-free arrangements, that have facilitated international travel to and from China. These include the recent unilateral visa-free policies for several countries, including France, Germany, Spain, Italy, and the Netherlands, mutual visa-free agreements with Malaysia, and plans for similar arrangements with Singapore and Thailand. China also announced earlier in the week that it will unilaterally grant visa-free entry to Swiss and Irish nationals. Since July 2023, China has removed visa requirements for citizens of 11 nations. According to Trip.com Group data, significant increases have been recorded in inbound search and booking volumes from countries such as Germany, Spain, and the Netherlands. Those with visa-free arrangements or plans for relaxed visa policies, such as Singapore, Thailand, and Malaysia, are among the top destinations favoured by Chinese tourists for the upcoming Chinese New Year. Moreover, since its launch in September 2023, Trip.com's "China Travel Guide", which provides information about hotel, transport, payment, and other travel-related issues, has served nearly 100,000 international travellers planning to visit China. Meanwhile, as of mid-January, outbound travel orders for the upcoming Chinese New Year holidays have surged more than 10 times compared to the previous year. For the wider Asian economy, Ms Sun maintained that its prospects remain robust, citing projections that it will contribute to around 50% of global GDP growth. The rapid development of the tourism industry in Asia, coupled with the strong purchasing power of Asian customers, has indicated the potential for sustained growth in the region. "We are committed to forging an influential network for our global partners, empowering them to welcome customers from every corner of the world," said Ms Sun. "Equally, we stand poised to usher Asian customers into the global arena, opening doors to boundless opportunities and creating pathways for unprecedented international success." About Trip.com GroupTrip.com Group is a leading global travel service provider comprising of Trip.com, Ctrip, Skyscanner, and Qunar. Across its platforms, Trip.com Group helps travellers around the world make informed and cost-effective bookings for travel products and services and enables partners to connect their offerings with users through the aggregation of comprehensive travel-related content and resources, and an advanced transaction platform consisting of apps, websites and 24/7 customer service centres. Founded in 1999 and listed on NASDAQ in 2003 and HKEX in 2021, Trip.com Group has become one of the best-known travel groups in the world, with the mission "to pursue the perfect trip for a better world". Find out more about Trip.com Group here: group.trip.com. Follow us on: Twitter, Facebook, LinkedIn, and YouTube.
SHANGHAI, Jan. 20, 2024 /PRNewswire/ -- On January 13, 2024 local time, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. officially announced the launch of its "Sanyou Super Trillion Peptide Molecule Discovery Platform". The Sanyou Super Trillion Peptide Molecule Discovery Platform is an integral part of the "Sanyou Super Trillion Innovative Biopharmaceutical Discovery Platform (STAL)", with a library capacity of up to 3.05×1012 CFU (30 trillion). The platform is suitable for the R&D of peptide-based drugs targeting diseases such as metabolism, tumors, as well as applications in medical imaging, molecular diagnostics, and other fields. Peptides obtained through the platform screening process can be further developed into various types of novel drugs, including PDCs, RDCs, antibody fusion proteins, and cyclic peptides. Sanyou Biopharmaceuticals has meticulously developed the Super Trillion Peptide Molecule Discovery Platform by collecting and analyzing tens of thousands of natural amino acid sequences. The platform incorporates unique patented fusion tag proteins, assisted by AI design, and employs phage display technology, matching eukaryotic expression with high-throughput screening. The rigorous establishment process of the platform ensures that the library sequences follow natural patterns, exhibit high diversity, and undergo comprehensive target validation. With Super Trillion Peptide Molecule Discovery Platform, Sanyou Pharmaceuticals can screen dozens to nearly a hundred lead molecules with significant sequence differences for a single target. The screened peptides have extremely high affinity, and with the assistance of AI and structure-guided optimization, they can achieve levels of nM and sub-nM. Dr. Guojun Lang, CEO of Sanyou Biopharmaceuticals, stated: "Peptide drugs have high specificity, low immunogenicity, minimal toxicity, and can be applied to various targets such as intracellular, extracellular, and membrane surfaces. The peptide drug market currently has tremendous growth potential, with global sales of nearly $20 billion in 2023 for just one drug, Semaglutide. Establishing a peptide library is crucial for peptide drug development, and it is a technological challenge. Leveraging years of experience in the filed of innovative biopharmaceuticals and the construction of the STAL Super Trillion Antibody Library platform, Sanyou Biopharmaceuticals has successfully overcome various technical challenges and completed the construction of the Super Trillion Peptide Molecule Discovery Platform. It is believed that the launch of the Sanyou Super Trillion Peptide Molecule Discovery Platform will overcome the development difficulties of peptide drugs, and greatly accelerate the development process of peptide drugs!" About Sanyou Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain, and has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS", to accomplish the mission "to make the R&D easy for innovative biologics". Sanyou has established an integrated innovative biologic drug R&D laboratory of twenty thousand square meters with advanced facilities, and has a professional team with the majority holding a Ph.D. or master degree. Sanyou has built three industry-leading innovative technology platforms featured by "super-trillion, integration, and intelligence" , which are comprised of more than 50 sub-platforms with the core innovative super-trillion phage display platform, and supported by platforms of material preparation, biologics discovery, molecule optimization, in vitro and in vivo efficacy, production cell line construction, upstream and downstream process development, preclinical R&D, industrialization development, etc. Sanyou's business network has expanded to all parts of the world, including Asia, US and Europe, and established branches in Boston, Philadelphia, San Diego and London. Sanyou has established friendly business relationships with more than 1000 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide. Sanyou received National-level certification as a high-tech enterprise and a Specialized and Sophisticated enterprise, and passed the ISO9001 quality assurance certification and GB/T intellectual property management system certification.
BEIJING and SAN FRANCISCO, Jan. 20, 2024 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK), a clinical-stage oncology company focusing on undruggable targets, announced data of glecirasib in patients with pancreatic cancer and other solid tumors in the oral abstract session at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium ("2024 ASCO GI"). As of December 6, 2023, the monotherapy global study of glecirasib enrolled 52 patients with pancreatic cancer and other solid tumors harboring KRAS G12C mutation in China, the United States, Europe, Israel and other regions, including 31 patients with pancreatic cancer, and 21 patients with other solid tumors (8 with biliary tract tumors, 3 with gastric cancer, 3 with small bowel cancer, 2 with appendix cancer, and 5 with other solid tumors). Among 50 patients with evaluable solid tumors, the confirmed objective response rate (cORR) was 48% (24/50) and the disease control rate (DCR) was 90% (45/50). For second-line and above KRAS G12C mutated pancreatic cancer patients, the cORR was 41.9% (13/31) and the DCR was 93.5% (29/31). The median progression-free survival (mPFS) was 5.6 months, and the median overall survival (mOS) was 10.7 months. In other solid tumor patients, the cORR was 57.9% (11/19), DCR was 84.2% (16/19), the mPFS was 7.0 months, and the mOS has not yet matured. The above safety and efficacy data are better than the published data of similar studies. Glecirasib has good tolerability and safety characteristics, the majority of treatment-related adverse events (TRAEs)are grades 1-2, and grade 3 or above TRAEs occurred in 25% of patients. No patient has permanently withdrawn from the study due to TRAE. Professor Lin Shen, director of Peking University Cancer Hospital gastroenterology department, is the principal investigator for this trial. She introduced at the conference, "Pancreatic cancer is a highly malignant tumor, and current patients lack effective standardized treatment methods, with a five-year overall survival rate of only 5%. Every year in China, nearly 1-2% of pancreatic cancer patients carry a KRAS G12C mutation, and the mutation rate in other solid tumors is also around 1%. The clinical data of glecirasib have preliminarily confirmed the efficacy in patients with pancreatic cancer and other solid tumors. Compared with the standard chemotherapy treatment, the ORR of glecirasib is higher, and the safety and tolerance is better. It is expected that glecirasib will accelerate the clinical development in pancreatic cancer and other solid tumors, bringing a better treatment option beyond chemotherapy for patients." Jacobio continues to explore the application of glecirasib in pancreatic cancer. Glecirasib's registrational pivotal study for pancreatic cancer was approved by CDE in July 2023, which became the first global pancreatic cancer KRAS G12C registrational clinical study. The study results will be used to submit NDA (New Drug Application) for pancreatic cancer. Based on the clinical efficacy and safety data from ongoing clinical trials, glecirasib was granted breakthrough therapy designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the pancreatic cancer patients with a KRAS G12C mutation who have progressed after frontline standard care treatment. Pancreatic cancer is a malignant tumor and there is a lack of effective treatment currently. The five-year overall survival rate is only 5%-10%. The BTD will expedite the clinical development of glecirasib and accelerate its early access to the patients. For more information, please visit the official website of the ASCO GI: https://conferences.asco.org/gi/program Conference Call Information Jacobio will host a live conference call on Jan. 23, 2024, at 9:30-10:30 (UTC+8). Participants must register in advance of the conference call. Registration Link: https://goldmansachs.zoom.us/webinar/register/WN_seUdoKXVQPSscqDJ8mM7uw About GlecirasibGlecirasib is a KRAS G12C inhibitor developed by Jacobio. A number of Phase I/II clinical trials of glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. This includes a pivotal clinical trial in NSCLC in China (patients enrollment has been completed); a monotherapy study for STK11 co-mutated NSCLC in the front-line setting, combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with Cetuximab in colorectal cancer, and a registrational pivotal clinical trial in pancreatic cancer. About Jacobio Pharma Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.
PORT OF SPAIN, Trinidad, Jan. 20, 2024 /PRNewswire/ -- The House of Angostura® prepares to celebrate as it counts down to its 200-year anniversary in 2024. With just a few weeks into the start of the new year, the House of Angostura® is ramping up preparations for a full year of festivities in honour of its bicentennial. 2024 will be an extraordinary year for the House of Angostura® as new product releases, commemorative limited editions, and incredible anniversary parties are planned worldwide. Trinidad & Tobago is a country known for its ability to throw a good party, as its scenes at Carnival can attest. Angostura® will carry this legendary, vibrant energy through its anniversary celebrations internationally. This historic year will see the House of Angostura® join an elite group of companies that has successfully maintained its relevance with each new generation of consumers for 200 years by continually innovating and building on its legacy. Every dash of ANGOSTURA® bitters has told a rich story for two centuries. The iconic bitters brand was born in 1824 when it was first formulated as a medicinal tincture in Venezuela by Dr Johann Seigert, surgeon general in Simon Bolivar's revolutionary army. In the 1870s, Dr Siegert's three sons moved to Trinidad, where Angostura® has been made ever since to the exact recipe as in 1824. In the 1950s, following the success of bitters, Angostura® decided to apply its know-how and passion for blending into crafting a range of beautiful rums. It now boasts one of the most highly awarded rum portfolios in the world. Angostura® today is one of Trinidad & Tobago's crown jewels, and the almost two centuries-old history is a testament to the company's grit, drive, and determination. Over the past 200 years, Angostura® has expanded from bitters and rum into other spirits, as well as low and no alcoholic beverages. 183 years after the original aromatic bitters, Angostura® introduced ANGOSTURA® orange bitters, and their latest innovation, ANGOSTURA® cocoa bitters, which was released in 2020 is helping to support the survival of Trinidad & Tobago's indigenous agricultural gem, Trinitario cocoa, and provides small-scale organic cocoa farmers with a sustainable future. House of Angostura® Chief Executive Officer, Laurent Schun comments: "For any company to reach 200 years is an incredible achievement. We're very proud and really excited going into our bicentennial year. We have so many plans that we're about to implement, including some exciting new products. 2024 is going to be 366 days of celebrating. As for the next 200 years, the future looks bright for Angostura". Connect with us at: Website: www.angostura.comFacebook: www.facebook.com/angosturalimitedInstagram: www.instagram.com/angosturattTwitter: https://twitter.com/Angosturatt
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
